Abnormal TREC screening: the diagnostic path to answers

An abnormal TREC screening result is a signal, not a diagnosis. It means that a newborn blood spot contains low or undetectable T-cell receptor excision circles, raising concern for T-cell lymphopenia and, in the most urgent cases, severe combined immunodeficiency (SCID). The result deserves rapid clinical attention, but it does not by itself establish SCID, predict the final prognosis, or determine whether a child will need hematopoietic stem cell transplantation.

The next steps are therefore structured rather than speculative: prompt review by a pediatric immunologist, confirmatory blood testing with flow cytometry, assessment of naïve T cells and other lymphocyte populations, and—when the immune phenotype supports it—molecular testing to identify the underlying cause. For families and clinicians asking about abnormal TREC screening next steps in pediatrics, the central principle is straightforward: move quickly, but allow each test to answer a different clinical question.

Interpreting the TREC screen: what the result can and cannot tell us

TRECs, or T-cell receptor excision circles, are small circular DNA fragments produced as developing T cells mature in the thymus. They are measured from a dried blood spot collected during newborn screening. A low TREC value suggests that few newly formed T cells are reaching the circulation, while an undetectable or near-zero result raises more urgent concern for profound T-cell lymphopenia.

That biological signal is clinically useful because infants with SCID often have very limited production of functional T cells. However, the TREC assay is a screening test. It is designed to identify babies who need further evaluation, not to separate every possible cause of low T-cell numbers at the first step.

A positive SCID screen can occur in several clinical settings:

• SCID or another profound primary T-cell disorder, in which T-cell production or function is severely impaired.
• Syndromic immune conditions, including disorders associated with chromosome 22q11.2 deletion or CHARGE syndrome.
• Prematurity, because immature thymic development can result in lower TREC production at birth.
• Secondary T-cell loss, including situations associated with congenital heart surgery or chylothorax.
• Transient neonatal conditions, such as temporary immune suppression or other circumstances affecting lymphocyte production and distribution.
• Technical or specimen-related factors, which may require review or repeat collection according to the local screening laboratory’s protocol.

The exact TREC threshold that triggers referral is not universal. Public health laboratories and screening centres may use different cutoffs, and some programs distinguish between a low positive result and an urgent result with undetectable or nearly undetectable TRECs. In the research and clinical frameworks used for follow-up, a value in the range of approximately 0–3 TRECs per microlitre is often treated as an urgent finding, but the laboratory’s own reporting category must guide the response.

An abnormal TREC screen starts the diagnostic pathway; it does not finish it.

The wording of the report matters. A result may be described as out of range, positive, inconclusive, or urgent, and those categories can lead to different timelines. An urgent result should prompt expedited referral to pediatric immunology, particularly when TRECs are undetectable or close to zero. A mildly reduced result in a premature infant may be handled through repeat screening or direct confirmatory testing, depending on the infant’s gestational age, clinical condition, and regional protocol.

While waiting for specialist review, the clinical team will usually examine the newborn’s overall condition, birth history, gestational age, transfusion history, congenital anomalies, infections, and any procedures that might influence lymphocyte counts. The screening result should never be interpreted in isolation from the clinical presentation.

Why flow cytometry is the first confirmatory test

The primary confirmatory test after an abnormal TREC result is immunophenotyping by flow cytometry. This test examines the infant’s circulating lymphocytes in detail, identifying both the number and proportion of major immune cell populations.

In practical terms, flow cytometry helps answer questions that the TREC assay cannot:

• How many T cells are present in the blood?
• Are CD3+ T cells severely reduced, moderately reduced, or within the expected range?
• What are the CD4+ and CD8+ T-cell counts?
• Are B cells and natural killer cells present?
• Are the T cells predominantly naïve, as expected in a newborn, or do they have a memory phenotype?
• Does the pattern suggest a primary developmental problem, maternal cell engraftment, or a secondary process?

The core panel generally includes CD3+ T cells, CD4+ helper T cells, CD8+ cytotoxic T cells, CD19+ or CD20+ B cells, and CD16+/CD56+ natural killer cells. Absolute counts are particularly important. Percentages alone can be misleading when the total white-cell count or absolute lymphocyte count is abnormal.

A newborn may have a relatively high percentage of T cells but still have an inadequate absolute number. Conversely, a low percentage can sometimes reflect expansion of another lymphocyte population rather than severe T-cell depletion. This is why the laboratory report must be interpreted alongside the complete blood count and the infant’s clinical status.

Naïve T cells are a critical part of the assessment

A newborn’s immune system should contain a substantial population of naïve T cells, reflecting recent thymic emigrants. These cells have not yet undergone extensive antigen-driven differentiation. Flow cytometry can assess markers such as CD45RA and CD27 to help quantify this naïve population.

This distinction is clinically important. An infant may have T cells detected in the blood, but those cells may not represent normal thymic output. They could include expanded memory T cells or, in rare circumstances, maternal T cells that have crossed the placenta and persisted in the infant. Maternal T-cell engraftment can complicate the interpretation of a positive SCID screen and requires specialist evaluation.

The initial flow cytometry therefore should not be reduced to a simple question of whether T cells are present. The more useful question is whether the infant has an appropriate pattern of T-cell quantity and maturation.

The timing of blood collection and the infant’s condition can affect results. A specialist may recommend repeat testing when the first sample is difficult to interpret, when the infant is premature, or when an acute illness could have altered lymphocyte distribution.

Distinguishing SCID from other causes of low T cells

A positive SCID screen creates understandable concern, but the clinical presentation after an abnormal TREC result is broader than SCID alone. The diagnostic pathway is designed to separate several conditions that can produce a similar screening signal while requiring different management.

Severe combined immunodeficiency

SCID is defined by profound impairment of T-cell development or function, often with additional effects on B-cell and natural killer cell compartments. The precise immune phenotype varies by genetic cause. Some forms present with very low or absent T cells, while B-cell and NK-cell numbers may be preserved or reduced in different combinations.

The diagnosis depends on the complete immune evaluation, not on the TREC value alone. Flow cytometry, functional testing, family history, genetic sequencing, and clinical findings are considered together. Infants with urgent screening results and a flow-cytometry pattern consistent with profound T-cell deficiency require immediate specialist management because untreated SCID can become life-threatening early in infancy.

22q11.2 deletion and related syndromic disorders

Conditions such as DiGeorge syndrome can affect thymic development and result in reduced T-cell numbers. The clinical presentation may include congenital heart disease, characteristic physical findings, low calcium levels, or other developmental features, although the range is wide.

The degree of immune impairment is variable. Some infants have a significant T-cell deficit, while others have a milder or transient reduction. This is one reason genetic and clinical assessment must be integrated with immunophenotyping rather than inferred from the TREC result.

Prematurity

Premature infants frequently have lower TREC counts than term newborns. The result may reflect developmental immaturity rather than a permanent primary immunodeficiency. Many screening programs use a repeat TREC strategy for infants whose initial result is low but not undetectable, with repeat collection around a corrected gestational age of 37 weeks in some protocols.

There is no single global approach. Some centres repeat the newborn screen, while others proceed directly to flow cytometry, particularly if the TREC value is extremely low, the infant is clinically unwell, or there are additional findings suggesting immune deficiency. The decision belongs to the local newborn-screening program and pediatric immunology team.

Secondary T-cell loss

The immune abnormality may be related to a condition or intervention outside the immune system. Congenital heart surgery, chylothorax, severe illness, and certain neonatal treatments can alter circulating lymphocyte numbers. The relevant history should be reviewed before labelling the infant with a lifelong primary immunodeficiency.

This distinction matters for quality of life and long-term planning. A transient or secondary cause may require monitoring and supportive care while the underlying problem resolves, whereas confirmed SCID leads to a highly specialized treatment pathway.

Maternal T-cell engraftment

Maternal lymphocytes can occasionally be detected in an infant with severe T-cell deficiency. These cells may have a memory phenotype rather than the naïve phenotype expected from normal infant thymic output. Their presence can create the appearance of circulating T cells without demonstrating adequate endogenous immune development.

The assessment of naïve T cells, including CD45RA+ CD27+ populations, helps the clinical team investigate this possibility. Additional specialized testing may be required, especially when the flow-cytometry pattern and clinical findings do not align neatly.

The diagnostic pathway for premature infants

Prematurity is one of the most common reasons an abnormal TREC screen requires careful timing rather than an immediate conclusion. The thymus and immune system are still developing, and the number of recent thymic emigrants may be lower in a preterm infant. That can reduce the TREC signal even when there is no permanent immunodeficiency.

The pathway generally revolves around four clinical questions:

1. How low was the TREC result?

An undetectable or near-zero result is more urgent than a borderline reduction. The numerical value and the screening laboratory’s interpretation determine whether the infant needs immediate flow cytometry, urgent immunology review, or repeat screening under a defined protocol.

2. How premature was the infant?

Gestational age affects the likelihood that a low TREC count reflects developmental immaturity. The team may use corrected gestational age when deciding whether a repeat screen is informative.

3. Is the infant clinically stable?

A well-appearing premature infant with a mildly reduced TREC level may follow a different route from an infant with infections, congenital anomalies, lymphopenia, or an urgent screen.

4. Are there additional reasons to suspect immune deficiency?

Congenital heart disease, unusual physical findings, persistent lymphopenia, or a family history of early infant deaths can lower the threshold for immediate confirmatory testing.

If repeat screening is chosen, it should not become a passive waiting period. The infant remains under clinical review, and any signs of infection or deterioration require prompt medical assessment. When the screen is urgently positive, direct specialist evaluation is generally more appropriate than relying solely on maturation and a later repeat sample.

The use of TREC and KREC testing also varies by screening program. TRECs focus primarily on newly formed T cells, while KRECs reflect aspects of B-cell development. A combined newborn screening approach can provide additional information about B-cell lymphopenia, but a normal KREC result does not make an abnormal TREC result irrelevant. Each assay addresses a different part of the immune system, and the follow-up plan should be based on the complete report.

From immunophenotyping to genetic sequencing

Once flow cytometry confirms significant or persistent T-cell lymphopenia, the next stage is to identify the cause. Genetic testing has become central to this process because childhood immunodeficiency can result from changes in many genes involved in thymic development, lymphocyte maturation, antigen-receptor signalling, DNA repair, cytokine pathways, and immune regulation.

The choice of test depends on the immune phenotype and the resources available. A pediatric immunologist may consider:

• Targeted testing, when the clinical and laboratory pattern strongly suggests a specific syndrome or gene.
• An inborn errors of immunity panel, which evaluates a curated group of genes associated with immune deficiency.
• Whole-exome or whole-genome sequencing, when the presentation is atypical, the first panel is unrevealing, or a broader analysis is clinically justified.
• Copy-number analysis, which can detect deletions or duplications such as 22q11.2 deletion when these are not adequately captured by a sequence-only approach.
• Family-based testing, which may help determine whether a variant is inherited, newly arising, or of uncertain significance.

Genetic sequencing does not replace immune phenotyping. A genetic variant must be interpreted in the context of the child’s clinical presentation, flow-cytometry findings, and—when needed—functional immune studies. A result reported as a variant of uncertain significance is not the same as a confirmed molecular diagnosis, and it should not be used alone to direct major treatment decisions.

The genetic stage can also clarify recurrence risk for the family. Depending on the inheritance pattern, parents may be offered testing and counselling, and future pregnancies may be eligible for prenatal or early targeted testing. Prenatal genetic screening is not interchangeable with newborn screening: prenatal tests address selected genetic risks before birth, while TREC newborn screening assesses a functional immune-development signal after birth.

What additional evaluations may be needed?

The precise work-up depends on the infant’s immune phenotype. The clinical team may evaluate:

• Complete blood count with differential and absolute lymphocyte count.
• Repeat lymphocyte subsets when the initial result is uncertain or a transient cause is possible.
• Naïve and memory T-cell populations.
• Immunoglobulin levels, interpreted in the context of maternal antibody transfer and age.
• T-cell function, when indicated.
• Testing for maternal lymphocyte engraftment.
• Evaluation for congenital anomalies or syndromic features.
• Genetic testing for sequence variants and copy-number changes.
• Targeted assessment of infections or other secondary causes.

The goal is not to order every available test at once. A well-designed management pathway uses the first results to determine which subsequent studies will be most informative. This staged approach can shorten the time to a meaningful diagnosis while avoiding incidental findings that create uncertainty without changing care.

Flow cytometry tells us what the immune system looks like now; genetic testing helps explain why that pattern developed.

How clinicians use the results to guide management

The diagnostic pathway and the management pathway proceed together. While confirmatory testing is underway, the pediatric immunology team considers the degree of immune compromise and the infant’s exposure to infection. The urgency is greatest when the TREC result is undetectable or nearly undetectable and flow cytometry shows profound T-cell deficiency.

Management decisions may include specialist infection-prevention guidance, review of vaccination plans, assessment of blood-product requirements, and a careful plan for monitoring. These decisions are individualized. They depend on the infant’s immune phenotype, current health, local protocols, and whether SCID or another significant immune disorder remains strongly suspected.

It is important not to make the opposite error: an abnormal TREC result should not automatically trigger the assumption that the infant requires transplantation. Hematopoietic stem cell transplantation is a treatment consideration for particular confirmed immune deficiencies, and the decision follows a specialist evaluation that includes immune function, genetic cause, infection status, donor options, and overall clinical condition.

For families, the interval between screening and diagnosis can feel unusually compressed and uncertain. The most useful questions are concrete:

• Was the TREC result borderline, low, or undetectable?
• Does the local program recommend repeat screening or immediate flow cytometry?
• What were the absolute CD3+, CD4+, and CD8+ counts?
• Were B cells and NK cells measured?
• Were naïve T cells assessed?
• Could prematurity, surgery, chylothorax, or another secondary condition explain the result?
• Has a pediatric immunologist reviewed the findings?
• What genetic test is being considered, and how will uncertain results be interpreted?
• What precautions or changes to routine care are recommended while the evaluation continues?

These questions do not replace medical care, but they make the route through the system clearer. They also help distinguish a laboratory flag from a confirmed diagnosis, which is essential for making decisions that protect the child without creating unnecessary alarm.

What the long-term outlook depends on

The prognosis after an abnormal TREC screen varies widely because the screen identifies a group of possible conditions rather than one disease. Some infants are ultimately found to have transient or secondary T-cell lymphopenia. Others have syndromic disorders with a variable immune course. A smaller but clinically urgent group has SCID or another severe inborn error of immunity requiring early definitive treatment.

The most important prognostic factors are the final diagnosis, the degree of T-cell deficiency, immune function, the presence or absence of serious infection, associated congenital conditions, and the speed with which specialized care begins. Early detection through newborn screening creates an opportunity to evaluate infants before severe infection develops, which can materially influence the management pathway and future quality of life.

The practical route is therefore clear:

1. Treat the screening result as clinically significant, without calling it a diagnosis.

2. Arrange prompt pediatric immunology review, especially for undetectable or near-zero TRECs.

3. Use flow cytometry to quantify T, B, and NK cells and assess naïve T-cell populations.

4. Investigate prematurity, syndromic features, surgery, chylothorax, maternal engraftment, and other secondary explanations.

5. Use genetic sequencing and copy-number testing to establish the underlying etiology when indicated.

6. Build management around the confirmed immune phenotype rather than the screening result alone.

An abnormal TREC screening result is a moment for disciplined follow-up, not panic. When each test is interpreted in the right sequence, families and clinicians can move from an unexpected newborn-screening signal to a specific diagnosis, a proportionate care plan, and a clearer view of the child’s long-term immune health.